The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. Peter Adolfsson is a Senior Physician at the hospitals of Halland, Kungsbacka and Halmstad.
He received his medical training at the Sahlgrenska Academy of the Gothenburg University and, subsequently, went on to specialize in Pediatrics, Sports Medicine and Endocrinology.
His scientific activities focus on the impact of diabetes technology, exercise and diabetes in general and sometimes physical activity beneath surface – scuba diving.
Moreover, he is one of the original founders of Diasend and participated as a board member until the merge with Glooko 2016 and in 2017 he received the ISPAD Prize for Innovation due to this work.
Peter leads courses in diabetes technology and has created educational guides regarding the use of rtCGM and is CGM - always stating that technology must be used appropriately to give the best results.
During the last 3 years Peter has focused on implementing digital health in diabetes care and the importance of a combined effort of technology, support and education. He has also implemented connected/smart pens into routine clinical practice in this effort.